Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Net Cash Flow: 2014-2024

Historic Net Cash Flow for Syndax Pharmaceuticals (SNDX) over the last 11 years, with Dec 2024 value amounting to -$141.3 million.

  • Syndax Pharmaceuticals' Net Cash Flow fell 70.42% to $8.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$16.2 million, marking a year-over-year decrease of 142.14%. This contributed to the annual value of -$141.3 million for FY2024, which is 163.90% down from last year.
  • According to the latest figures from FY2024, Syndax Pharmaceuticals' Net Cash Flow is -$141.3 million, which was down 163.90% from $221.1 million recorded in FY2023.
  • Over the past 5 years, Syndax Pharmaceuticals' Net Cash Flow peaked at $221.1 million during FY2023, and registered a low of -$147.6 million during FY2022.
  • Its 3-year average for Net Cash Flow is -$22.6 million, with a median of -$141.3 million in 2024.
  • In the last 5 years, Syndax Pharmaceuticals' Net Cash Flow surged by 1,078.66% in 2020 and then slumped by 238.31% in 2022.
  • Syndax Pharmaceuticals' Net Cash Flow (Yearly) stood at $90.6 million in 2020, then increased by 17.75% to $106.7 million in 2021, then plummeted by 238.31% to -$147.6 million in 2022, then skyrocketed by 249.81% to $221.1 million in 2023, then slumped by 163.90% to -$141.3 million in 2024.